Covered recipient · General Payments record
MUHAMMAD MASAB
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2018–2024
$2,822.12
- Reported across 87 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,430.55 | 68 |
| Education | $16.46 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $169.18 | 7 |
| Daiichi Sankyo Inc. | $164.52 | 11 |
| EISAI INC. | $122.63 | 5 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $121.55 | 5 |
| Bayer HealthCare Pharmaceuticals Inc. | $88.00 | 4 |
| Acerta Pharma LLC | $65.80 | 3 |
| Merck Sharp & Dohme Corporation | $64.88 | 3 |
| Astellas Pharma US Inc | $61.53 | 3 |
| PFIZER INC. | $59.33 | 3 |
| SOBI, INC | $49.53 | 1 |
| Incyte Corporation | $49.42 | 2 |
| BeiGene USA, Inc. | $49.14 | 2 |
| E.R. Squibb & Sons, L.L.C. | $47.53 | 3 |
| PUMA BIOTECHNOLOGY, INC. | $46.05 | 2 |
| Janssen Biotech, Inc. | $29.86 | 2 |
| TerSera Therapeutics LLC | $25.77 | 1 |
| Immunocore Limited | $23.51 | 1 |
| Blueprint Medicines Corporation | $22.46 | 1 |
| SERVIER PHARMACEUTICALS LLC | $21.65 | 1 |
| Tempus AI, Inc | $21.53 | 1 |
| Celgene Corporation | $20.14 | 1 |
| Ipsen Biopharmaceuticals, Inc | $19.45 | 1 |
| ABBVIE INC. | $19.38 | 1 |
| ADC Therapeutics America, Inc. | $19.36 | 1 |
| Myriad Genetic Laboratories, Inc. | $17.83 | 1 |
| Lilly USA, LLC | $16.12 | 1 |
| Gilead Sciences, Inc. | $16.08 | 1 |
| Exelixis Inc. | $14.78 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (69)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.